Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Oct 12;333(15):970-4.
doi: 10.1056/NEJM199510123331504.

Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations

Affiliations
Free article

Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations

A M Goldstein et al. N Engl J Med. .
Free article

Abstract

Background: A gene on chromosome 9p, p16INK4, has been implicated in the pathogenesis of cutaneous malignant melanoma in 19 melanoma-prone families. In 10 of these kindreds mutations that impaired the function of the p16INK4 protein (p16M alleles) cosegregated with the disease. By contrast, in the other nine kindreds the mutation did not alter the function of p16INK4 (p16W alleles). We looked for differences in clinical and genetic epidemiologic features in these two groups of families.

Methods: We compared the median ages at diagnosis of melanoma, number of melanomas, thickness of the tumors, and number of nevi in the kindreds. We estimated prospectively the risks of melanoma or other cancers in families followed for 6 to 18 years and the risks of other cancers since 1925 (the entire period) by comparing the number of cancer cases observed with the number expected.

Results: The risk of invasive melanoma was increased by a factor of 75 in kindreds with p16M alleles and a factor of 38 in kindreds with p16W alleles. Although this difference was not significant (P = 0.14), there was a striking difference in the risk of other tumors. In kindreds with p16M alleles, the risk of pancreatic cancer was increased by a factor of 13 in the prospective period (2 cases observed, 0.15 expected; standardized incidence ratio, 13.1; 95 percent confidence interval, 1.5 to 47.4) and by a factor of 22 in the entire period (7 cases observed, 0.32 expected; standardized incidence ratio, 21.8; 95 percent confidence interval, 8.7 to 44.8). In contrast, we found no cases of pancreatic cancer in kindred with p16W alleles.

Conclusions: The development of pancreatic cancer in kindreds prone to melanoma may require a p16M mutation. Genetic factors, such as the kind of mutation found in p16INK4, may explain the inconsistent occurrence of other cancers in these kindreds.

PubMed Disclaimer

Comment in

Similar articles

Cited by

  • Hereditary pancreatic and hepatobiliary cancers.
    Haddad A, Kowdley GC, Pawlik TM, Cunningham SC. Haddad A, et al. Int J Surg Oncol. 2011;2011:154673. doi: 10.1155/2011/154673. Epub 2011 Jun 28. Int J Surg Oncol. 2011. PMID: 22312493 Free PMC article.
  • Familial pancreatic cancer.
    Rieder H, Bartsch DK. Rieder H, et al. Fam Cancer. 2004;3(1):69-74. doi: 10.1023/B:FAME.0000026822.67291.a1. Fam Cancer. 2004. PMID: 15131409 Review.
  • CDKN2A germline mutations in familial pancreatic cancer.
    Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grützmann R, Colombo-Benkmann M, Ziegler A, Hahn SA, Rothmund M, Rieder H. Bartsch DK, et al. Ann Surg. 2002 Dec;236(6):730-7. doi: 10.1097/00000658-200212000-00005. Ann Surg. 2002. PMID: 12454511 Free PMC article.
  • Common and differential features of liver and pancreatic cancers: molecular mechanism approach.
    Saki K, Mansouri V, Asri N, Fathi M, Razzaghi Z. Saki K, et al. Gastroenterol Hepatol Bed Bench. 2021 Fall;14(Suppl1):S87-S93. Gastroenterol Hepatol Bed Bench. 2021. PMID: 35154607 Free PMC article.
  • The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
    Lesueur F, de Lichy M, Barrois M, Durand G, Bombled J, Avril MF, Chompret A, Boitier F, Lenoir GM; French Familial Melanoma Study Group; Bressac-de Paillerets B, Baccard M, Bachollet B, Berthet P, Bonadona V, Bonnetblanc JM, Caron O, Chevrant-Breton J, Cuny JF, Dalle S, Delaunay M, Demange L, De Quatrebarbes J, Doré JF, Frénay M, Fricker JP, Gauthier-Villars M, Gesta P, Giraud S, Gorry P, Grange F, Green A, Huiart L, Janin N, Joly P, Kérob D, Lasset C, Leroux D, Limacher JM, Longy M, Mansard S, Marrou K, Martin-Denavit T, Mateus C, Maubec E, Olivier-Faivre L, Orlandini V, Pujol P, Sassolas B, Stoppa-Lyonnet D, Thomas L, Vabres P, Venat L, Wierzbicka E, Zattara H. Lesueur F, et al. Br J Cancer. 2008 Jul 22;99(2):364-70. doi: 10.1038/sj.bjc.6604470. Epub 2008 Jul 8. Br J Cancer. 2008. PMID: 18612309 Free PMC article.

LinkOut - more resources